WO2016004093A3 - Therapeutic compositions including galectin-3 inhibitors and uses thereof - Google Patents
Therapeutic compositions including galectin-3 inhibitors and uses thereof Download PDFInfo
- Publication number
- WO2016004093A3 WO2016004093A3 PCT/US2015/038645 US2015038645W WO2016004093A3 WO 2016004093 A3 WO2016004093 A3 WO 2016004093A3 US 2015038645 W US2015038645 W US 2015038645W WO 2016004093 A3 WO2016004093 A3 WO 2016004093A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitors
- phe
- lys
- arg
- aromatic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of galectin-3 inhibitors, and/or naturally or artificially occurring derivatives, variants, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to galectin-3 inhibitors and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2',6'-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2',6'-Dmt-Lys-Phe-NH2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462019535P | 2014-07-01 | 2014-07-01 | |
US62/019,535 | 2014-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016004093A2 WO2016004093A2 (en) | 2016-01-07 |
WO2016004093A3 true WO2016004093A3 (en) | 2016-03-03 |
Family
ID=55020090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/038645 WO2016004093A2 (en) | 2014-07-01 | 2015-06-30 | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016004093A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2968443T (en) | 2013-03-15 | 2021-12-10 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
EP3960754A3 (en) | 2014-05-16 | 2022-07-06 | Protagonist Therapeutics, Inc. | Alpha4beta7 integrin thioether peptide antagonists |
RU2736637C9 (en) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Peptidic interleukin-23 receptor inhibitors for oral administration and use thereof for treating inflammatory intestinal diseases |
EP3200812B8 (en) | 2014-10-01 | 2021-04-28 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
JP7498108B2 (en) | 2017-08-03 | 2024-06-11 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー | Compounds and their uses for the prevention and treatment of medical disorders - Patents.com |
TW201920234A (en) * | 2017-09-11 | 2019-06-01 | 美商領導醫療有限公司 | Opioid agonist peptides and uses thereof |
EP3466975A1 (en) * | 2017-10-05 | 2019-04-10 | Laboratoire Français du Fractionnement et des Biotechnologies | A specific binding molecule directed against galectin-3 protein |
US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
CN112672765A (en) * | 2018-06-29 | 2021-04-16 | 格莱科斯生物医药公司 | Conjugates |
WO2020096002A1 (en) * | 2018-11-08 | 2020-05-14 | 国立大学法人香川大学 | Brown/beige adipocyte activating agent containing d-allulose as active ingredient |
CA3127113A1 (en) | 2019-01-30 | 2020-08-06 | Dongxu Sun | Anti-gal3 antibodies and uses thereof |
EP3997105A4 (en) | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2021064729A1 (en) * | 2019-10-02 | 2021-04-08 | Patchor Ltd. | Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof |
CN112745372B (en) * | 2019-10-31 | 2022-07-12 | 深圳先进技术研究院 | Functional saccharide molecule based on TDG molecular skeleton and preparation method thereof |
KR20220129030A (en) * | 2020-01-13 | 2022-09-22 | 트루바인딩 아이엔씨. | Anti-Gal3 Antibodies and Methods of Use |
CN115279782A (en) | 2020-01-15 | 2022-11-01 | 詹森生物科技公司 | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases |
WO2021146441A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
EP4132537A4 (en) * | 2020-04-07 | 2024-05-15 | G3P, Inc. | Methods and compositions for preventing and treating retinal nerve damage |
US20230279052A1 (en) * | 2020-06-22 | 2023-09-07 | Stealth Biotherapeutics Inc. | Prodrugs of mitochondria-targeting oligopeptides |
WO2021262708A1 (en) * | 2020-06-22 | 2021-12-30 | Stealth Biotherapeutics Corp. | Prodrugs of mitochodria-targeting oligopeptides |
US11939361B2 (en) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of Interleukin-23 receptor |
WO2022240741A1 (en) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
WO2023023256A1 (en) * | 2021-08-18 | 2023-02-23 | Oculogenex Inc. | Aav-mediated gene transfer for retinopathy |
AU2022388722A1 (en) * | 2021-11-09 | 2024-05-23 | Truebinding, Inc. | Methods of treating or inhibiting cardiovascular diseases |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610841B1 (en) * | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
WO2005001023A2 (en) * | 2003-05-01 | 2005-01-06 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
US20070134279A1 (en) * | 2005-12-09 | 2007-06-14 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
US20100311664A1 (en) * | 2004-01-23 | 2010-12-09 | Szeto Hazel H | Methods for reducing oxidative damage |
US20130244957A1 (en) * | 2003-02-04 | 2013-09-19 | Hazel H. Szeto | Methods for preventing or treating mitochondrial permeability transition |
-
2015
- 2015-06-30 WO PCT/US2015/038645 patent/WO2016004093A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610841B1 (en) * | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
US20130244957A1 (en) * | 2003-02-04 | 2013-09-19 | Hazel H. Szeto | Methods for preventing or treating mitochondrial permeability transition |
WO2005001023A2 (en) * | 2003-05-01 | 2005-01-06 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
US20100311664A1 (en) * | 2004-01-23 | 2010-12-09 | Szeto Hazel H | Methods for reducing oxidative damage |
US20070134279A1 (en) * | 2005-12-09 | 2007-06-14 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
Also Published As
Publication number | Publication date |
---|---|
WO2016004093A2 (en) | 2016-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016004093A3 (en) | Therapeutic compositions including galectin-3 inhibitors and uses thereof | |
WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
WO2015183995A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
WO2014165607A3 (en) | Aromatic-cationic peptide formulations, compositions and methods of use | |
EA201892395A1 (en) | DRUG COMPOSITIONS OF LSD1 INHIBITOR | |
PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
WO2014205317A3 (en) | Cyclic peptides as protein targeting agents | |
PH12015502002B1 (en) | Tripeptide epoxy ketone protease inhibitors | |
MX2014002171A (en) | Combination treatments for hepatitis c. | |
MX2021004639A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors. | |
EA201592250A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseases | |
EA201690287A1 (en) | 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY | |
WO2012030160A3 (en) | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
JO3326B1 (en) | Tripeptide Epoxy Ketone Protease Inhibitors | |
UA111599C2 (en) | COMPOSITION OF CASPOFUNGIN | |
NZ708016A (en) | Lyophilized preparations of melphalan flufenamide | |
MX2016002580A (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases. | |
CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
MX2021010297A (en) | Human plasma kallikrein inhibitors. | |
WO2016168553A8 (en) | Deuterated obeticholic acid | |
MX2022013450A (en) | Pharmaceutical formulations. | |
WO2015183985A3 (en) | Therapeutic compositions including naphthoquinones and uses thereof | |
WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15814758 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15814758 Country of ref document: EP Kind code of ref document: A2 |